60

Hunan Fangsheng Pharmaceutical Co LtdSHG 603998 Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Oct, 2024

Last price

Market cap $B

0.651

Micro

Exchange

XSHG - Shanghai Stock Exchange

603998.SS Stock Analysis

60

Neutral

Based on Eyestock quantitative analysis, 603998.SS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

51/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

7.1 %

Undervalued

Market cap $B

0.651

Dividend yield

2.60 %

Shares outstanding

428.55 B

Hunan Fangsheng Pharmaceutical Co., Ltd. engages in the manufacture, distribution, research and development of pharmaceutical products. The company is headquartered in Changsha, Hunan and currently employs 2,808 full-time employees. The company went IPO on 2014-12-05. The firm's main products include Xuesaitong Dispersible Tablets, Xuesaitong Tablets, Tenghuang Jiangu Tablets, Dieda Huoxue Capsules, Lysine Dimension B12 Granules, Cefixoxime Tablets and Jinying Capsules. The firm distributes its products primarily in domestic market.

View Section: Eyestock Rating